Ingunn Stefansson

Ingunn Stefansson

Auto-generated profile, based on publicly available information

Ingunn Stefansson

Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, N-5021, Norway; Department of Pathology, Haukeland University Hospital, Bergen, Norway

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KBKatharina Bischof
Katharina Bischof
SKStian Knappskog
Stian Knappskog
ISIngunn Stefansson
Ingunn Stefansson
ECEmmet Mc Cormack
Emmet Mc Cormack
JTJone Trovik
Jone Trovik
Line BjørgeLine Bjørge
Line Bjørge
Uterine serous carcinoma (USC) is a rare but aggressive subtype of endometrial carcinoma. Large-scale comprehensive efforts have resulted in an improved molecular understanding of its pathogenesis, and the p53 pathway has been proposed as a key player and is potentially targetable. Here we attempt to further portray the p53 pathway in USC by assessing p53 isoform expression. We applied quantitative Real-Time PCRs (RT-qPCR) for expression analyses of total p53 mRNA as well as quantitative distinction of p53β, p53γ, and the total mRNA of amino-terminal truncated Δ40p53 and Δ133p53 in a retrospective cohort of 37 patients with USC. TP53 mutation status was assessed by targeted massive parallel sequencing. Findings were correlated with clinical data. The p53 isoform expression landscape in USCs was heterogeneous and dominated by total Δ133p53, while the distinct p53β and p53γ variants were found at much lower levels. The isoform expression profiles varied between samples, while their expression was independent of TP53 mutation status. We found high relative p53γ expression to be associated with reduced progression-free survival (PFS). This is the first indication that elevated p53γ expression is associated with reduced PFS in USC. This single-center study may offer some insight in the landscape of p53 isoform expression in USC, but further validation studies are crucial to understand the context-dependent and tissue-specific role of the p53 isoform network in gynecological cancer.

6 February 2020 in Cancers
Verified
Journal Article
Open access
PDF file
TFTina Fonnes
Tina Fonnes
Elin StrandElin Strand
Elin Strand
KFKristine E. Fasmer
Kristine E. Fasmer
HBHege F. Berg
Hege F. Berg
HEHeidi Espedal
Heidi Espedal
ECEmmet Mc Cormack
Emmet Mc Cormack
Imaging of clinically relevant preclinical animal models is critical to the development of personalized therapeutic strategies for endometrial carcinoma. Although orthotopic patient-derived xenografts (PDXs) reflecting heterogeneous molecular subtypes are considered the most relevant preclinical models, their use in therapeutic development is limited by the lack of appropriate imaging modalities. Here, we describe molecular imaging of a near-infrared fluorescently labeled monoclonal antibody targeting epithelial cell adhesion molecule (EpCAM) as an in vivo imaging modality for visualization of orthotopic endometrial carcinoma PDX. Application of this near-infrared probe (EpCAM-AF680) enabled both spatio-temporal visualization of development and longitudinal therapy monitoring of orthotopic PDX. Notably, EpCAM-AF680 facilitated imaging of multiple PDX models representing different subtypes of the disease. Thus, the combined implementation of EpCAM-AF680 and orthotopic PDX models creates a state-of-the-art preclinical platform for identification and validation of new targeted therapies and corresponding response predicting markers for endometrial carcinoma.

4 October 2017 in APMIS
Verified
Journal Article
Closed access
PDF file
NVNicole C.M. Visser
Nicole C.M. Visser
HWHenrica M.J. Werner
Henrica M.J. Werner
CKCamilla Krakstad
Camilla Krakstad
KMKaren K. Mauland
Karen K. Mauland
JTJone Trovik
Jone Trovik
ISIngunn M. Stefansson
Ingunn M. Stefansson

1 January 2002
Verified
Journal Article
Closed access
ISIngunn Stefansson
Ingunn Stefansson
LALars A Akslen
Lars A Akslen
NMNicola MacDonald
Nicola MacDonald
ARAndy Ryan
Andy Ryan
SDSoma Das
Soma Das
HSHelga B Salvesen
Helga B Salvesen

27 March 2024 in Tidsskrift for Den norske legeforening
Verified
Journal Article
Open access
PDF file
ILIngvild Kathrin Lokøy
Ingvild Kathrin Lokøy
IBInga Sofie Bakken
Inga Sofie Bakken
EWElisabeth Wik
Elisabeth Wik
ISIngunn Marie Stefansson
Ingunn Marie Stefansson
27.03.2024: Kort rapport - Median alder ved diagnosetidspunktet var 72 år.

23 October 2025 in Human Pathology
Verified
Journal Article
Open access
ISIngunn M. Stefansson
Ingunn M. Stefansson
GKGøril Knutsvik
Gøril Knutsvik
JAJarle Arnes
Jarle Arnes
KCKarin Collett
Karin Collett
CACecilie Askeland
Cecilie Askeland
LALars A. Akslen
Lars A. Akslen
Androgen receptor (AR) is reported to be expressed in the majority of breast cancers (BC) with different expression rates across breast cancer subtypes. AR might influence cell proliferation, DNA damage repair, apoptosis, cellular migration and metastasis. The prognostic role of AR varies significantly across breast cancer subtypes. Here, we studied the expression pattern and prognostic relevance of AR in BC, with special focus on molecular stratification. We analyzed a large population-based cohort of breast carcinomas with long and complete follow up. AR expression was evaluated by immuno-histochemistry on tissue microarray slides. Loss of AR was significantly associated with features indicative of poor prognosis (larger tumor diameter, higher histologic grade, estrogen (ER) and progesterone hormone (PR) receptor negativity, elevated proliferation by Ki67, and expression of basal markers). Also, expression of AR was associated with lower proliferation by Ki67 regardless of ER-status. Regarding survival, loss of AR was significantly correlated with decreased breast cancer-specific survival in univariate analysis, both in the overall cohort and within the Luminal A and basal-like (CK5/6+) subgroups. In summary, AR expression emerged as a favorable prognostic factor in breast cancer, demonstrating independent prognostic significance within the basal-like (CK5/6+) subgroup.